Search Results - "Baytemur, Naziyet Kose"

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer by Esen, Selin Akturk, Ergun, Yakup, Erol, Cihan, Arikan, Rukiye, Er, Muhammed Muhiddin, Atci, Muhammed Mustafa, Topcu, Atakan, Ucar, Gokhan, Akagunduz, Baran, Aykan, Musa Baris, Ozen, Mirac, Baytemur, Naziyet Kose, Ozcelik, Melike, Sahin, Elif, Guven, Denizcan, Menekse, Serkan, Ak, Naziye, Teker, Fatih, Kut, Engin, Sakalar, Teoman, Alan, Ozkan, Kacan, Turgut, Turhal, Nazim Serdar, Kilickap, Saadettin, Turker, Sema, Sendur, Mehmet Ali Nahit, Kostek, Osman, Karaagac, Mustafa, Sakin, Abdullah, Turk, Haci Mehmet, Caglayan, Dilek, Cihan, Sener, Acikgoz, Yusuf, Uncu, Dogan

“…Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2…”
Get full text

The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study by Guven, Deniz Can, Acar, Ramazan, Yekeduz, Emre, Bilgetekin, Irem, Baytemur, Naziyet Kose, Erol, Cihan, Ceylan, Furkan, Sendur, Mehmet Ali, Demirci, Umut, Urun, Yuksel, Karadurmus, Nuri, Erman, Mustafa, Kilickap, Saadettin

“…Immunotherapy improves overall survival (OS) in the second and later lines of renal cell carcinoma (RCC) treatment. Recent studies have suggested that…”
Get full text

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy by Karacin, Cengiz, Oksuzoglu, Berna, Demirci, Ayşe, Keskinkılıç, Merve, Baytemür, Naziyet Köse, Yılmaz, Funda, Selvi, Oğuzhan, Erdem, Dilek, Avşar, Esin, Paksoy, Nail, Demir, Necla, Göksu, Sema Sezgin, Türker, Sema, Bayram, Ertuğrul, Çelebi, Abdüssamet, Yılmaz, Hatice, Kuzu, Ömer Faruk, Kahraman, Seda, Gökmen, İvo, Sakin, Abdullah, Alkan, Ali, Nayır, Erdinç, Uğraklı, Muzaffer, Acar, Ömer, Ertürk, İsmail, Demir, Hacer, Aslan, Ferit, Sönmez, Özlem, Korkmaz, Taner, Celayir, Özde Melisa, Karadağ, İbrahim, Kayıkçıoğlu, Erkan, Şakalar, Teoman, Öktem, İlker Nihat, Eren, Tülay, Urul, Enes, Mocan, Eda Eylemer, Kalkan, Ziya, Yıldırım, Nilgün, Ergün, Yakup, Akagündüz, Baran, Karakaya, Serdar, Kut, Engin, Teker, Fatih, Demirel, Burçin Çakan, Karaboyun, Kubilay, Almuradova, Elvina, Ünal, Olçun Ümit, Oyman, Abdilkerim, Işık, Deniz, Okutur, Kerem, Öztosun, Buğra, Gülbağcı, Burcu Belen, Kalender, Mehmet Emin, Şahin, Elif, Seyyar, Mustafa, Özdemir, Özlem, Selçukbiricik, Fatih, Kanıtez, Metin, Dede, İsa, Gümüş, Mahmut, Gökmen, Erhan, Yaren, Arzu, Menekşe, Serkan, Ebinç, Senar, Aksoy, Sercan, İmamoğlu, Gökşen İnanç, Altınbaş, Mustafa, Çetin, Bülent, Uluç, Başak Oyan, Er, Özlem, Karadurmuş, Nuri, Erdoğan, Atike Pınar, Artaç, Mehmet, Tanrıverdi, Özgür, Çiçin, İrfan, Şendur, Mehmet Ali Nahit, Oktay, Esin, Bayoğlu, İbrahim Vedat, Paydaş, Semra, Aydıner, Adnan, Salim, Derya Kıvrak, Geredeli, Çağlayan, Yavuzşen, Tuğba, Doğan, Mutlu, Hacıbekiroğlu, İlhan

“…There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor…”
Get full text

The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC) by Bilgetekin, Irem, Dogan, Mehmet, Karacin, Cengiz, Basal, Fatma Bugdayci, Esin, Ece, Ucar, Gokhan, Isak, Ozlem Aydin, Imamoglu, Goksen Inanc, Yildiran Keskin, Gul Sema, Erturk, Ismail, Aktas, Burak Yasin, Kose Baytemur, Naziyet, Aydin, Kubra, Ozturk, Selcuk Cemil, Aksel, Bulent, Karadurmus, Nuri, Kandemir, Olcay, Oksuzoglu, Berna, Demirci, Umut

“…Abstract only e15587 Background: Expanded RAS analysis is essential for the selection of biologic agents in mCRC. RAS mutations indicates anti-EGFR…”
Get full text

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer by Kahraman, Seda, Erul, Enes, Seyyar, Mustafa, Gumusay, Ozge, Bayram, Ertugrul, Demirel, Burcin Cakan, Acar, Omer, Aksoy, Sercan, Baytemur, Naziyet Kose, Sahin, Elif, Cabuk, Devrim, Basaran, Gul, Paydas, Semra, Yaren, Arzu, Guven, Deniz Can, Erdogan, Atike Pinar, Demirci, Umut, Yasar, Alper, Bayoglu, İbrahim Vedat, Hizal, Mutlu, Gulbagci, Burcu, Paksoy, Nail, Davarci, Sena Ece, Yilmaz, Funda, Dogan, Ozlem, Orhan, Sibel Oyucu, Kayikcioglu, Erkan, Aytac, Ali, Keskinkilic, Merve, Mocan, Eda Eylemer, Unal, Olcun Umit, Aydin, Esra, Yucel, Hakan, Isik, Deniz, Eren, Onder, Uluc, Basak Oyan, Ozcelik, Melike, Hacibekiroglu, Ilhan, Aydiner, Adnan, Demir, Hacer, Oksuzoglu, Berna, Cilbir, Ebru, Cubukcu, Erdem, Cetin, Bulent, Oktay, Esin, Erol, Cihan, Okutur, Sadi Kerem, Yildirim, Nilgun, Alkan, Ali, Selcukbiricik, Fatih, Aksoy, Asude, Karakas, Yusuf, Ozkanli, Gulhan, Duman, Berna Bozkurt, Aydin, Dincer, Dulgar, Ozgecan, Er, Muhammed Muhiddin, Teker, Fatih, Yavuzsen, Tugba, Aykan, Musa Baris, Inal, Ali, Iriagac, Yakup, Kalkan, Nurhan Onal, Keser, Murat, Sakalar, Teoman, Menekse, Serkan, Kut, Engin, Bilgin, Burak, Karaoglanoglu, Muge, Sunar, Veli, Ozdemir, Ozlem, Turhal, Nazim Serdar, Karadurmus, Nuri, Yalcin, Bulent, Sendur, Mehmet Ali Nahit

“…Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for…”
Get full text

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study) by Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Atcı, Muhammed Mustafa, Kahraman, Seda, Kılıçkap, Saadettin, Güven, Deniz Can, Keskinkılıç, Merve, Ayhan, Murat, Eren, Önder, Mustafayev, Fatma Nihan Akkoç, Yaman, Şebnem, Bayram, Ertuğrul, Ertürk, İsmail, Özcan, Erkan, Korkmaz, Mustafa, Akagündüz, Baran, Erdem, Dilek, Telli, Tuğba Akın, Aksoy, Asude, Üskent, Necdet, Baytemür, Naziyet Köse, Gülmez, Ahmet, Aydın, Dinçer, Şakalar, Teoman, Arak, Hacı, Tatlı, Ali Murat, Ergün, Yakup, Ak, Naziye, Ünal, Çağlar, Özgün, Mehmet Alpaslan, Yalçın, Bülent, Öztop, İlhan, Algın, Efnan, Sakin, Abdullah, Aydıner, Adnan, Yumuk, Perran Fulden, Şendur, Mehmet Ali Nahit

“…Introduction Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced…”
Get full text

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study by Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Kılıçkap, Saadettin, Atcı, Muhammed Mustafa, Kahraman, Seda, Keskinkılıç, Merve, Bilgetekin, İrem, Ayhan, Murat, Tural, Deniz, Eren, Önder, Akkoç Mustafayev, Fatma Nihan, Yaman, Şebnem, Tatlı, Ali Murat, Bayram, Ertuğrul, Kutlu, Yasin, Ertürk, İsmail, Özcan, Erkan, Gülmez, Ahmet, Korkmaz, Mustafa, Akagündüz, Baran, Erdem, Dilek, Telli, Tuğba Akın, Aksoy, Asude, Üskent, Necdet, İriağaç, Yakup, Baytemür, Naziyet Köse, Aydın, Dinçer, Şakalar, Teoman, Arak, Hacı, Selçukbiricik, Fatih, Ergün, Yakup, Korkmaz, Taner, Ak, Naziye, Ünal, Çağlar, Akdeniz, Nadiye, Özgün, Mehmet Alpaslan, Öksüzoğlu, Berna, Yalçın, Bülent, Öztop, İlhan, Algın, Efnan, Sakin, Abdullah, Aydıner, Adnan, Yumuk, Perran Fulden, Şendur, Mehmet Ali Nahit

“…In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. This retrospective trial included…”
Get full text

Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group) by Erol, Cihan, Sakin, Abdullah, Başoğlu, Tuğba, Özden, Ercan, Çabuk, Devrim, Doğan, Mutlu, Öksüzoğlu, Berna, Yıldırım, Hasan Çağrı, Öner, İrem, Eryılmaz, Melek Karakurt, Dülgar, Özgecan, Aydın, Dinçer, Doğan, Neslihan, Özen, Miraç, Hacıbekiroğlu, İlhan, Özdemir, Nuriye, Gürler, Fatih, Paksoy, Nail, Karabulut, Senem, Aksoy, Asude, Hızal, Mutlu, Kahraman, Seda, Şen, Erdem, Paydaş, Semra, Çılbır, Ebru, Fırat, Feyza, Akdeniz, Nadiye, Özçelik, Melike, Oyman, Abdilkerim, Baytemür, Naziyet Köse, Acar, Ramazan, Almuradova, Elvina, Karabulut, Bülent, Şakalar, Teoman, Arak, Hacı, Değerli, Ezgi, Türker, Sema, Alan, Özkan, Er, Özlem, Taşçı, Elif Şenocak, Demir, Nazan, Çavdar, Eyyüp, Turhal, Serdar, Dede, Didem Şener, Akıncı, Muhammed Bülent, Yalçın, Bülent, Yumuk, Fulden, Yalçın, Şuayib, Şendur, Mehmet Ali Nahit

“…Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic…”
Get full text

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal carcinoma by Aktürk Esen, Selin, Ergun, Yakup, Erol, Cihan, Arikan, Rukiye, Er, Muhammed Muhiddin, Atci, Muhammed Mustafa, Topçu, Atakan, Uçar, Gökhan, Akagündüz, Baran, Aykan, Musa Bariş, Özen, Miraç, Baytemur, Naziyet Köse, Özçelik, Melike, Şahin, Elif, Güven, Denizcan, Menekşe, Serkan, Ak, Naziye, Teker, Fatih, Kut, Engin, Şakalar, Teoman, Alan, Özkan, Kaçan, Turgut, Turhal, Nazim Serdar, Kiliçkap, Saadettin, Türker, Sema, Şendur, Mehmet Ali Nahit, Köstek, Osman, Karaağaç, Mustafa, Sakin, Abdullah, Türk, Haci Mehmet, Çağlayan, Dilek, Cihan, Şener, Açikgöz, Yusuf, Uncu, Doğan

“…Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma…”
Get full text